The Predicting Role of Serum TSGF and sIL-2R for the Lymph Node Metastasis of Papillary Thyroid Carcinoma

Table 2

The relationship between serum sIL-2R and TSGF level and clinicopathological parameters in patients with PTC.

	sIL-2R				TSGF
	Low	High			Low	High
Gender
Male	18 (45.0)	22 (55.0)	4.464	0.035	20 (50.0)	20 (50.0)	0.301	0.583
Female	105 (63.6)	61 (36.4)			91 (54.8)	75 (45.2)
Age
≤45 years	65 (63.1)	38 (36.9)	0.989	0.32	54 (52.4)	49 (47.6)	0.176	0.675
>45 years	58 (56.3)	45 (43.7)			57 (55.3)	46 (45.7)
Tumor size
≤1 cm	99 (61.1)	63 (38.9)	0.62	0.431	89 (54.9)	73 (45.1)	0.34	0.56
>1 cm	24 (54.5)	20 (45.5)			22 (50.0)	22 (50.0)
Nodular goiter
No	47 (63.5)	27 (37.5)	0.695	0.404	39 (52.7)	35 (47.3)	0.065	0.799
Yes	76 (57.6)	56 (42.4)			72 (54.5)	60 (45.5)
HT
No	100 (60.2)	66 (39.8)	0.101	0.751	91 (54.8)	75 (45.2)	0.301	0.583
Yes	23 (57.5)	17 (42.5)			20 (50.0)	20 (50.0)
Focality
Unifocality	76 (63.9)	43 (36.1)	2.024	0.155	72 (60.5)	47 (39.5)	4.97	0.026
Multifocality	47 (54.0)	40 (46.0)			39 (44.8)	48 (55.2)
Capsular invasion
No	86 (63.2)	50 (36.8)	2.069	0.15	72 (52.9)	64 (47.1)	0.143	0.705
Yes	37 (52.9)	33 (47.1)			39 (55.7)	31 (44.3)
LNM
No	71 (56.3)	55 (43.7)	1.522	0.217	75 (59.5)	51 (40.5)	4.154	0.042
Yes	52 (65.0)	28 (35.0)			36 (45.0)	44 (55.0)

.